Press release
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\nThe Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) – November 12-15, 2021\n\nTitle: ARO-AAT Treatment Reduces Intra-hepatic Z-AAT Leading to Improved Parameters of Liver Health and Fibrosis Regression\nAuthors: Pavel Strnad, et al.\nPublication Number: LP11\nSession: Late-breaking Abstract Posters\n\nTitle: ARO-HSD, An Investigational RNAi Therapeutic, Demonstrates Reduction in ALT and Hepatic HSD17B13 mRNA and Protein in Patients with NASH or Suspected NASH\nAuthors: Lung-Yi Mak, et al.\nPublication Number: LP13\nSession: Late-breaking Abstract Posters\n\nTitle: Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator (CAM) JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection (CHB): Results from the Phase 2B REEF-1 Study\nAuthors: Man Fung Yuen, et al.\nPublication Number: LO10\nSession: Late Breaking Session 2\n\nAmerican Heart Association (AHA) Scientific Sessions 2021 – November 13-17, 2021\n\nTitle: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia\nAuthors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.\nSession: The Future of Lipidology: Novel and Emerging Interventions for Lipid Disorders\n\nJefferies London Healthcare Conference – November 16-19, 2021\n\nNovember 16, 2021, 3:50 p.m. GMT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\nPiper Sandler 33rd Annual Healthcare Conference – November 30-December 2, 2021\n\nNovember 30, 2021 – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\nA copy of the presentation materials and/or live webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA i...